Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients

Background/Objectives : The prevalence of inflammatory bowel disease (IBD) in spondyloarthritis (SpA) patients is unknown. Our objective was to assess the prevalence of undiagnosed IBD in SpA patients, including those with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA). Additionally, we...

Descripción completa

Detalles Bibliográficos
Autores: Sanz-Sanz, Jesús|||0000-0001-8740-0063, Gutiérrez Casbas, Ana|||0000-0002-5460-4139, Plaza, Zulema, Gratacós, Jordi|||0000-0003-4007-4103, Rodríguez-Lago, Iago|||0000-0003-1133-4578, Marín Jiménez, Ignacio|||0000-0001-5424-2484, Trujillo-Martín, Elisa, Pérez-Pampín, Eva|||0000-0003-0319-4456, Barreiro de-Acosta, Manuel|||0000-0001-5915-1477, Hernández-Hernández, María Vanesa|||0000-0003-1306-8461, Carrillo-Palau, Marta, García Vivar, María Luz|||0000-0001-8822-9843, Muñoz-Villafranca, María Carmen, Ladehesa-Pineda, Maria Lourdes|||0000-0002-3890-2224, Iglesias-Flores, Eva, Merino-Argumánez, Carolina|||0000-0002-3089-5330, González-Lama, Yago|||0000-0003-3896-7914, Arévalo Salaet, Marta|||0000-0002-1863-7494, Calvet, Xavier|||0000-0002-6278-9663, Díaz-González, Federico|||0000-0002-4139-9295
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:dnet:uabarcelona_::97404f761ed72da24a01772c9964a17f
Acceso en línea:https://ddd.uab.cat/record/327733
https://dx.doi.org/urn:doi:10.3390/jcm14134569
Access Level:acceso abierto
Palabra clave:Prevalence undiagnostic
Inflammatory bowel disease
Fecal calprotectin
Axial spondylarthritis
Psoriatic arthritis
Descripción
Sumario:Background/Objectives : The prevalence of inflammatory bowel disease (IBD) in spondyloarthritis (SpA) patients is unknown. Our objective was to assess the prevalence of undiagnosed IBD in SpA patients, including those with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA). Additionally, we examined fecal calprotectin (FC) levels in relation to the accuracy of IBD diagnosis. Methods : EISER was a cross-sectional, multicenter, observational, rheumatologist-gastroenterologist collaborative study. Patients with SpA naïve to biologics were recruited. Demographic and clinical characteristics, disease activity, and treatment information were collected. Patients with FC ≥ 80 µg/g or IBD-related symptoms underwent a colonoscopy or video capsule endoscopy. Receiver operating characteristic analysis assessed the predictive value of FC for IBD diagnosis. Results : Of the 570 patients recruited, 494 were evaluable for the main outcome, 248 (50.2%) had axSpA, and 246 (49.8%) had PsA. Overall, 28/494 patients were diagnosed with IBD (5.7%, 95%CI 3.6-7.7). Sorted by clinical entity, 22 (8.9%, 95%CI 5.3-12.4) axSpA and 6 (2.4%, 95%CI 0.5-4.4) PsA patients had a diagnosis of IBD: 24 (86%, 95%CI 79.4-92.6) had ileal/ileocolonic Crohn's disease (CD), 3 (11%, 95%CI 5.1-16.9) unclassified IBD, and 1 (3.5%, 95%CI 0.0-6.9) ulcerative colitis. The ROC curve for FC and IBD diagnosis (AUC: 0.870, p.

Similares en LA Referencia